Starpharma Holdings Ltd. (OTCMKTS:SPHRY – Get Free Report) was the recipient of a large growth in short interest in the month of July. As of July 15th, there was short interest totaling 1 shares, a growth of ∞ from the June 30th total of 0 shares. Based on an average trading volume of 1,653 shares, the days-to-cover ratio is presently 0.0 days. Currently, 0.0% of the company’s stock are sold short.
Starpharma Stock Performance
Shares of SPHRY remained flat at $4.69 during trading hours on Thursday. Starpharma has a 1 year low of $0.67 and a 1 year high of $5.70. The stock’s 50-day simple moving average is $4.76 and its two-hundred day simple moving average is $3.98.
About Starpharma
Starpharma is a clinical-stage biopharmaceutical company specializing in the development of dendrimer-based products across infectious disease, oncology and ophthalmology. Its proprietary dendrimer platform, DEP™ (Dendrimer Enhanced Products), enables precise molecular engineering to enhance drug delivery, targeting and safety profiles. The company’s lead product, VivaGel®, is a topical microbicide that has been approved in multiple markets for the treatment and prevention of bacterial vaginosis and is in clinical development for antiviral applications.
In addition to VivaGel, Starpharma is advancing pipeline candidates that leverage DEP technology to improve the performance of established and novel therapeutic agents.
Featured Stories
- Five stocks we like better than Starpharma
- Microsoft Just Flipped the AI Spending Narrative Overnight
- Qualcomm’s Turnaround Is Working, So Why Is Wall Street Selling?
- Meta’s Earnings Show Why Wall Street Is Losing Patience With AI Spending
- Can Starbucks Keep This Turnaround Going? The Latest Results Say Yes
Receive News & Ratings for Starpharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Starpharma and related companies with MarketBeat.com's FREE daily email newsletter.
